Quantifying Inflammation Can Add to CV Risk Prediction Even in No-Contrast Scans
Experts hope the FAI score can become the next big tool in personalized risk assessment, though costs remain unknown.
Photo Credit: SCCT
CHULA VISTA, CA—On top of calculating a patient’s coronary artery calcium (CAC) score, using CT to quantify their coronary inflammation can help refine risk assessment, no matter whether contrast is used, according to new data.
Tested in the ORFAN study, the CT-derived fat attenuation index (FAI) score measures vascular inflammation and has been linked with better prediction of future cardiovascular events.
The new findings, presented by Kenneth Chan, MD (Oxford University Hospitals, England), recently at the 2026 Society of Cardiovascular Computed Tomography (SCCT) meeting, show a similar prognostic value for predicting cardiovascular mortality over time with the tool. It outperforms CAC scanning alone, even among the generally lower-risk population of patients not indicated to receive a contrast CT.
“Previously, the work has been done predominantly on contrast-enhanced angiograms,” he told TCTMD. “But we know that a lot of more patients have only the noncontrast calcium score scans. So now we can measure and quantify inflammation from these scans as well, which can be applicable to a lot more patients.”
The technology used to measure FAI (CaRi-Heart; Caristo Diagnostics) is currently funded by research grants as a pilot program within the National Health Service and is under review by the US Food and Drug Administration.
In wider practice, Chan said, it will likely lead to cost savings because the technology will “identify the patients who are at risk and prevent an event from happening, which is quite costly for each acute heart attack.” However, more cost-effectiveness research, as well as comparisons with broader measures of inflammation like high-sensitivity C-reactive protein, is needed, he said.
Session co-moderator and SCCT President Ronen Rubinshtein, MD (Edith Wolfson Medical Center, Holon, Israel), likened tools like the FAI score to a “noninvasive biopsy.” To TCTMD, he said that looking beyond the calcium score is the next frontier of cardiovascular risk prediction.
“The finding of inflammation or other findings around the coronary vessels may be as important as the plaque itself,” he said. “Not all plaques are the same, and some patients with inflammation around the vessel, even if they have a zero calcium score, they’re still at risk or at higher risk for adverse events down the road.”
The field needs to realize, Rubinshtein continued, that “it’s not just the plaque and it’s not just the amount of calcification, but it is our ability to see or to observe pathophysiology processes like inflammation around the coronary vessel that can predict events.”
As Effective Without Contrast
For the analysis, Chan and colleagues looked at 19,159 patients (mean age 56 years; 51.4% male) from the ORFAN study who received either contrast-enhanced coronary CT angiography (CTA) or noncontrast gated CT at nine centers in the United Kingdom. Notably, the population was ethnically diverse, with 40.5% identifying as white patients, 14.8% as Asian or Asian British, 6.2% as Black or Black British, and 38.3% other.
Over a median follow-up of 6.8 years, the researchers saw that the FAI score as measured using CTA with contrast “significantly stratified risk in patients across all the calcium score categories,” Chan reported. “However, what is more striking is that the prognostic value is strongest among patients with zero calcium score. . . . The hazard ratio for CV mortality per standard deviation of FAI score is almost 1.5 times compared to [none].”
This finding remained significant after adjustment for modifiable risk factors including hypertension, diabetes, lipids, and smoking.
“Excitingly, the prognostic value was very similar in the noncontrast cardiac CT [group],” Chan said. “We saw that calcium score has great prognostic value, but addition of the FAI score measured from contrast or noncontrast CT significantly improved the discrimination for the risk. And even accounting for quantitative plaque analysis for non-calcified plaque, the addition of FAI score significantly improved the prediction of cardiac mortality.”
In context, though patients with a CAC of more than 100 are already considered to be at high risk for an event, the FAI score was able to reclassify some of them to an even higher risk category. Even among patients with a CAC score of 1-99, the FAI helped refine risk for some. Chan argued that assessing for inflammation in these cohorts would be especially beneficial in guiding clinical management to prevent events.
Future Potential
The FAI score came up in several places throughout the SCCT meeting, including during a poster presentation that showed the tool’s ability to pick up risk-enhancing coronary inflammation in a population of well-treated post-MI patients.
The study included 466 patients (mean age 63 years; 79% male) enrolled in FORTIFY, an ongoing phase IIb trial comparing the investigational fully human monoclonal antibody orticumab (Abcentra), which targets oxidized LDL, to placebo in stable post-MI patients with persistent coronary inflammation. Almost all CTA scans taken (99%) were analyzable for the FAI score, including 16% with excellent quality, 49% with good quality, and 34% with acceptable quality. Moreover, despite high use of guideline-directed medical therapy, 63% of patients had at least one artery with an FAI score above the 50th percentile, which is tied to increased risk of MACE.
Todd Villines, MD (University of Virginia School of Medicine, Charlottesville), who presented the data, told TCTMD the first interesting finding from their study was that although “this is a group we were a little bit nervous about imaging because they have lots of stents [and] many of these people have had more than one infarct,” using the FAI score is still an option that can make a difference. “This is a population that if you’re meticulous with your image acquisition, you can get very interpretable images,” Villines noted.
Beyond that, “the second really cool [finding] is that essentially about half of these patients who were exceedingly well treated . . . still had significant inflammation,” he said. “These are people, if I saw them in the clinic, I would say, ‘Wow you’re doing great.’”
Ritu Thamman, MD (University of Pittsburgh Medical Center, PA), who presented the “enthusiast’s view” of the FAI score during a discussion session on the first day of SCCT, told TCTMD she sees a lot of potential for the technology.
“We’re just at the tip of the iceberg,” she told TCTMD. “It opens this whole other [line of] questioning.” Thamman gave the example of how people of South Asian descent tend to have greater proportions of fat than others, and a tool like the FAI score can help them differentiate what their individual fat composition means for their risk with more precision.
“At least at this point in the evidence, it’ll be an add-on,” she said. “[For] someone who’s already on a statin, already at LDL goal, . . . certainly if they’re young and they have a family history, and they’ve already had an MI, [I’d want to know if I can] reduce the inflammation even more. In those patients, I would consider it even if they’re not diabetics. But that’s going to take a while.”
Also, Thamman continued, “another useful aspect of this [is] you’ll be able to do serial studies and be able to assess is my therapy effective or not. We can’t really do that with a CAC score, because it’s going to go up if I put them on a statin. That doesn’t really tell me future risk, but this has that potential.”
Yael L. Maxwell is Senior Medical Journalist for TCTMD and Section Editor of TCTMD's Fellows Forum. She served as the inaugural…
Read Full BioSources
Chan K. Quantifying coronary inflammation on contrast or non-contrast cardiac CT enhances cardiovascular risk stratification beyond coronary calcium score and plaque volume. Presented at: SCCT 2026. July 11, 2026. Chula Vista, CA.
Villines TC. High rates of analyzable coronary CTA images suitable for coronary inflammation (FAI-Score) analysis: the FORTIFY study. Presented at: SCCT 2026. July 10, 2026. Chula Vista, CA.
Disclosures
- Chan, Rubinshtein, Villines, and Thamman report no relevant conflicts of interest.
Comments